What's in Pierre Fabre Dermo Cosmetique's pipeline?

Pierre Fabre Dermo Cosmetique has 2 drugs in our index: 1 marketed, 0 filed, 1 in Phase 3, 0 in Phase 2, 0 in Phase 1.

Which companies overlap with Pierre Fabre Dermo Cosmetique's portfolio?

Top competitors by shared drug class: Galderma R&D.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/pierre-fabre-dermo-cosmetique.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Pierre Fabre Dermo Cosmetique — Portfolio Competitive Intelligence Brief

Pierre Fabre Dermo Cosmetique pipeline: 1 marketed, 0 filed, 1 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 1 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Amorolfine (Antifungal)	Amorolfine (Antifungal)	marketed	Morpholine antifungal	Lanosterol 14α-demethylase (CYP51)	Dermatology / Infectious Disease
RV3391A	RV3391A	phase 3			Dermatology

Therapeutic area mix

Dermatology · 1
Dermatology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Galderma R&D · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Pierre Fabre Dermo Cosmetique:

Cite this brief

Drug Landscape (2026). Pierre Fabre Dermo Cosmetique — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/pierre-fabre-dermo-cosmetique. Accessed 2026-05-16.